Welcome to our dedicated page for PUMA BIOTECHNOLOGY news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on PUMA BIOTECHNOLOGY stock.
Puma Biotechnology Inc (PBYI) is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative treatments for cancer. Specializing in the in-licensing of drug candidates, Puma focuses on therapies that have undergone initial clinical testing, aiming to advance these candidates for commercial use. The company's core mission is to enhance cancer care and improve patient outcomes through cutting-edge treatments.
One of Puma Biotechnology's flagship products is NERLYNX, an oral version of neratinib. This drug is specifically designed for the treatment of HER2-positive breast cancer. NERLYNX works by inhibiting the HER2 receptor, which plays a key role in the growth and spread of breast cancer cells. The effectiveness and commercial success of NERLYNX highlight Puma's commitment to providing innovative solutions in oncology.
In addition to NERLYNX, Puma is developing alisertib, a selective inhibitor of aurora kinase A. This small-molecule drug disrupts mitosis, leading to the apoptosis of rapidly proliferating tumor cells. Alisertib is targeted at various forms of cancer, making it a versatile addition to Puma's portfolio.
Puma Biotechnology's strategy involves collaboration and partnerships to bring their innovations to market. The company has a robust financial foundation, enabling it to invest in research and development while pursuing effective commercialization strategies. Puma's ongoing projects and recent achievements demonstrate its role as a significant player in the biopharmaceutical industry, consistently pushing the boundaries of cancer treatment.
For investors and stakeholders, Puma Biotechnology's focus on innovative cancer therapies and its strategic development pipeline offer promising opportunities. The company's commitment to enhancing treatment outcomes ensures it remains at the forefront of the biopharmaceutical sector.
Puma Biotechnology (NASDAQ: PBYI) announced on March 1, 2022, the approval of an inducement restricted stock unit award for 9,375 shares to a new non-executive employee. This award, part of Puma’s 2017 Employment Inducement Incentive Award Plan, vests over three years, with a third vesting on the first anniversary and one-sixth every six months thereafter, contingent on continued service. The grant complies with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for the new hire.
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported its financial results for Q4 and the full year 2021. The company generated $51.0 million in product revenue for Q4 2021, a slight increase from $50.0 million in Q4 2020, while full-year product revenue fell to $189.1 million from $196.7 million. Puma achieved a net income of $4.2 million in Q4 2021 versus a net loss of $15.0 million in Q4 2020. Total revenue for 2021 was $253.2 million, an increase from $225.1 million in 2020. The company expects key milestones in the coming year related to its HER2-positive breast cancer treatment.
Puma Biotechnology, Inc. (NASDAQ: PBYI) will hold a conference call on Thursday, March 3, at 1:30 p.m. PST/4:30 p.m. EST to discuss its fourth quarter and full year 2021 financial results. Investors can participate by calling 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on Puma's website. The replay will be accessible one hour after the call for 90 days. Puma focuses on developing innovative cancer treatments, including its FDA-approved drug, NERLYNX® (neratinib), for HER2-positive breast cancer.
Puma Biotechnology (NASDAQ: PBYI) has announced the approval of inducement restricted stock unit awards for three new non-executive employees on February 1, 2022. A total of 24,375 shares will be awarded under the 2017 Employment Inducement Incentive Award Plan, with shares vesting over three years. One-third will vest after one year, and one-sixth will vest every six months thereafter, contingent on continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent joining the company.
Puma Biotechnology (NASDAQ: PBYI) announced on January 18, 2022, that its Board's Compensation Committee approved the grant of a restricted stock unit award covering 11,250 shares to a new non-executive employee. This award, part of Puma’s 2017 Employment Inducement Incentive Award Plan, vests over three years, with one-third vesting on the first anniversary of the vesting commencement date (January 1, 2022). The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4), facilitating the employee's entry into the company.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced two significant updates to the NCCN Clinical Practice Guidelines for breast cancer treatment involving neratinib (NERLYNX®). First, neratinib is now recommended for adjuvant therapy in high-risk HR-positive, HER2-positive breast cancer patients. Second, dose escalation is endorsed to enhance tolerability, aligning with FDA-approved labeling from June 2021. These updates aim to heighten awareness and accessibility of neratinib for patients, as emphasized by experts in oncology.
Puma Biotechnology (NASDAQ: PBYI) provided an update on its corporate presentation at the H.C. Wainwright BioConnect Conference on January 10, 2022. The company estimated selling about 3,454 bottles of NERLYNX® in the U.S. during Q4 2021. This figure is preliminary and may be subject to adjustments. NERLYNX, which is used for treating specific breast cancer types, was approved by the FDA in 2017 and 2020 for various applications, including adjuvant and metastatic settings. Additional details regarding the presentation are available on Puma's Investor Relations website.
Puma Biotechnology (NASDAQ: PBYI) will present at the H.C. Wainwright BioConnect Virtual Conference, with CEO Alan H. Auerbach speaking on January 10, 2022, at 7:00 a.m. EST. The presentation will be available on the company’s website for 30 days. Puma focuses on developing innovative cancer therapies, including NERLYNX® (neratinib), approved for specific HER2-positive breast cancer treatments. NERLYNX is also indicated for advanced cases after prior therapies. Further details can be found on www.pumabiotechnology.com.
Puma Biotechnology presented promising results from the Phase II SUMMIT trial at the 2021 San Antonio Breast Cancer Symposium. The trial evaluated neratinib combined with fulvestrant and trastuzumab for patients with hormone receptor-positive, HER2-mutant metastatic breast cancer previously treated with CDK4/6 inhibitors. The non-randomized cohort showed a 46.2% confirmed objective response rate. In triple-negative breast cancer cohorts, a 33.3% confirmed objective response rate was observed. Safety results indicated diarrhea as the most frequent adverse event, with 45.5% reporting grade 3 diarrhea in HR-positive patients.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced the grant of inducement restricted stock units covering 13,125 shares to two new non-executive employees on December 1, 2021. The awards, part of Puma’s 2017 Employment Inducement Incentive Award Plan, vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize new hires.
FAQ
What is the current stock price of PUMA BIOTECHNOLOGY (PBYI)?
What is the market cap of PUMA BIOTECHNOLOGY (PBYI)?
What does Puma Biotechnology Inc (PBYI) specialize in?
What is NERLYNX?
What is alisertib?
What is Puma Biotechnology's approach to drug development?
How does NERLYNX work?
What types of cancer is alisertib aimed at treating?
Does Puma Biotechnology collaborate with other companies?
What are some recent achievements of Puma Biotechnology?
What is the company's financial condition?
Why is Puma Biotechnology significant in the biopharmaceutical industry?
